Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC1029 | Angiotensin (1-7) |
| Endogenous peptide fragment. Induces vasorelaxation through release of NO and prostaglandins, perhaps through activation of a non-AT1, non-AT2 receptor, Mas. Counteracts the vasoconstrictive and proliferative effects of angiotensin II and stimulates vasopressin (anti-diuretic hormone) release in vivo. | |
| BCC1031 | Angiotensin III (human, mouse) |
| Endogenous vasoconstrictor peptide, formed from the conversion of angiotensin II in vivo. Acts at both AT1 and AT2 receptors and increases vasopressin (anti-diuretic hormone) release and blood pressure. | |
| BCC1032 | Gap 26 |
| Peptide, corresponding to residues 63 - 75 of connexin 43, which is a gap junction blocker. Attenuates rhythmic contractile activity of rabbit arterial smooth muscle (IC50 = 28.4 μM). Also inhibits IP3-induced ATP release, without inhibiting gap junctional coupling in endothelial cells. | |
| BCC1033 | Gap 27 |
| Peptide derived from connexin 43 that is a selective gap junction blocker. Attenuates ACh-induced arterial relaxation and reduces K+-mediated smooth muscle repolarization in endothelium-intact vessels in vitro. | |
| BCC1034 | Dynamin inhibitory peptide |
| Peptide inhibitor of the GTPase dynamin; competitively blocks binding of dynamin to amphiphysin thus prevents endocytosis when administered intracellularly. Reduces GABAA receptor internalization and increases miniature ISPC amplitude and frequency in neurons expressing GABAA receptors. Cell-permeable version also available. | |
| BCC1037 | Angiotensin 1/2 + A (2 - 8) |
| Potent endogenous vasoconstrictor peptide; derivative of angiotensin (Ang) II. Elicits pressor and renal vasoconstrictor effects in rodents via the AT1 receptor; inhibited by Candesartan but not by AT2 receptor ligands in vivo. Displays a similar affinity for AT1 and AT2 receptors as angiotensin II in vitro (Ki values are 1.6 and 2.3 nM at AT1 and AT2 receptors); also increases inositol phosphate accumulation with a similar potency to Ang II (EC50 = 6.7 nM). | |
| BCC1040 | Parathyroid Hormone (1-34), bovine |
| Parathyroid hormone (PTH) receptor agonist. Increases calcium and inorganic phosphate levels in the serum of young rats. Increases osteocalcin concentrations in the serum of old rats without affecting calcium or phosphate levels. | |
| BCC1041 | Peptide YY(3-36), PYY, human |
| NPY Y2 receptor agonist. Peripheral administration inhibits food intake in mice. This effect is greater when Peptide YY (3-36) is administered in combination with GLP-1 (7-36) (Cat.No. 2082). | |
